{
    "nct_id": "NCT04582201",
    "official_title": "A Phase 1/2 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 or Influenza",
    "inclusion_criteria": "1. Voluntarily agree to participate and can provide informed consent or have a duly appointed health care proxy establish which/who has the authority to consent on behalf of the participant\n2. Inpatient hospitalization\n3. Evidence of SARS-CoV-2 infection with the diagnosis of moderate to severe ARDS secondary to SARS-CoV-2 or influenza per Berlin definition (ARDS 2012)\n4. Participants, or study participant's duly appointed health care proxy with the authority to consent on behalf of the participant, must consent to placement of a central venous access line for the administration of agenT-797\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Currently participating and receiving study therapy of an investigational agent that is not registered for any other indication\n2. Clinically significant cardiomyopathy\n3. Pre-existing respiratory disease, such as significant chronic obstructive pulmonary disease requiring home oxygen, hospitalization, or systemic steroid use during the past year\n4. \"Significant\" pulmonary hypertension, defined as mean pulmonary artery pressure â‰¥ 20 millimeters of mercury and evidence of right ventricular dysfunction or enlargement\n5. Receipt of vaccines containing live virus within 4 weeks prior to first dose of study treatment\n6. Known hypersensitivity to donor-derived cell therapy or their preservation solution\n7. Active systemic bacterial or fungal infection or viral co-infection\n8. Pregnant or lactating women\n9. Presence of multiorgan dysfunction syndrome; no organ failure should be seen other than the organ of interest, which is the lung",
    "miscellaneous_criteria": ""
}